SURFAXIN GETS ORPHAN DRUG DESIGNATION FROM EMEA.
Discovery Laboratories, Inc. (Nasdaq:DSCO), Doylestown, Pa. has
announced that the Commission of the European Communities has designated
Surfaxin(r) as an Orphan Medicinal Product. This designation . . .
CRUCELL LICENSES PER.C6 TECHNOLOGY TO GLAXOSMITHKLINE.
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL)
and allied contract manufacturer DSM Biologics have announced that
Crucell has signed a PER.C6 research license agreement . . .
GENEPHARM BEGINS REGISTRATION OF FIVE ANTI-CANCER DRUGS.
Generic medicines pharmaceutical company Genepharm Australasia
(ASX:GAA), Melbourne, has submitted for registration with the
Therapeutic Goods Administration (TGA) five important . . .
KINEXUS VALIDATES PLK1 AS CANCER DRUG TARGET.
Kinexus Bioinformatics Corporation, Vancouver, a Canadian
proteomics company, has announced the validation of its unique approach
for protein kinase drug target discovery with the publication of . . .
AUSTCANCER APPOINTS SINGAPORE DISTRIBUTOR FOR REVISYS.
Australian Cancer Technology Limited ("AustCancer") (ASX:
ACU) has announced that its US subsidiary, ACT (USA) Inc, has appointed
Hengzi Technology Investment Pte Ltd as exclusive distributor of . . .
UNIGEN/INCA HEALTH TO DEVELOP PLANT-DERIVED HEALTH
PRODUCTS.
Unigen Pharmaceuticals, Inc., Broomfield, Colo., a leading research
and development facility and supplier of proprietary, biologically
active plant-derived ingredients to the natural products . . .
UK FETAL MEDICINE FOUNDATION APPROVES DELFIA PRENATAL
ASSAYS.
PerkinElmer, Inc. (NYSE: PKI), Boston, Mass., leading provider of
drug discovery, life science research and analytical solutions, has
announced that its DELFIA(R) Xpress first trimester prenatal . . .
EPITAN ACQUIRES THREE DERMATOLOGY PRODUCTS.
EpiTan Limited [ASX: EPT], Melbourne, Australia, has acquired three
products as part of its strategy to establish a specialty pharmaceutical
business focused on dermatology.
Two of the products, . . .
VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), Cambridge,
Mass., and Mitsubishi Pharma Corporation have signed an agreement to
develop and commercialize VX-950,
Vertex's investigational oral . . .
AMRAD TO DEMERGE ANTI-INFECTIVES BUSINESS.
Australian biotech Amrad will spin-out its advanced anti-
infectives drug portfolio into a new corporate entity, Avexa Limited.
The spin-out will be effected by a demerger to existing . . .
RANBAXY LAUNCHES RANICLOR CHEWABLE CEPHALOSPORIN TABLET.
Ranbaxy Pharmaceuticals Inc. (RPI), Jacksonville, Fla., a wholly
owned subsidiary of Ranbaxy Laboratories Limited (RLL), has launched
Raniclor(TM) (cefaclor tablets, chewable). Raniclor is the . . .
GPC BIOTECH GETS U.S. PATENT FOR ANTI-CANCER CELL
INHIBITOR.
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30) has
announced that the U.S. Patent and Trademark Office has issued a patent
with claims covering RGB-286199, cell cycle inhibitor, to GPC . . .
DECODE INITIATES PHASE IIA CLINICAL TRIAL FOR DG031.
deCODE genetics (Nasdaq:DCGN), Reykjavik, Iceland, has initiated
its ten-week, information-rich Phase IIa clinical trial of DG031, its
developmental compound for the prevention of heart attack. The . . .
AUSTCANCER TO ACQUIRE U.S. VACCINE DEVELOPER.
The Board of Australian Cancer Technology ("AustCancer")
(ASX:ACU) has signed an agreement to acquire, through its wholly- owned
U.S. subsidiary Adjuvantys Inc., the business of . . .
UNIGEN/UNIV. OF PANAMA SIGN PLANT COLLECTION PACT.
Unigen Pharmaceuticals, Inc., Broomfield, Colo., a research and
development facility and supplier of proprietary, biologically active
plant-derived ingredients to the natural products and . . .
BTG GETS EXCLUSIVE LICENSE TO NEW CLASS OF CANCER DRUG.
BTG (LSE: BGC),West Conshohocken, Pa., the intellectual property
and technology commercialization company, has concluded a license and
research collaboration agreement with Cancer Research . . .
PROMETIC BIOSCIENCES ACHIEVES SECOND MILESTONE OF
LICENSE.
ProMetic Life Sciences, Montreal, (PLI:TSX) has announced that its
subsidiary ProMetic BioSciences Limited (ProMetic) has achieved the
second milestone of its License Agreement with AM-Pharma B.V.
. . .
NOVARTIS SANDOSTATIN LAR APPROVED IN JAPAN FOR
ACROMEGALY.
Novartis, Basel, Switzerland, has announced that the Japanese
health authority has approved Sandostatin LAR (octreotide acetate for
injectable suspension) for the treatment of acromegaly and . . .
DRAGON GETS HUMAN G-CSF LICENSING RIGHTS EXCLUDING CHINA.
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG), Vancouver, has
entered into an agreement with Suzhou Zhongkai Bio-Pharmaceuticals
Company Limited ("Zhongkai") to in-license the exclusive . . .
US ONCOLOGY CENTER OFFERS AUSTCANCER'S REVISYS
SUPPLEMENTS.
Through its US subsidiary ACT (USA), Australian Cancer Technology
("AustCancer" ASX:ACU) has announced that its full range of
revisys specialty nutritional supplements are available at the . . .
|
|